Characteristics of patients with B-type chronic lymphocytic leukemia (B-CLL)
| Patient Code . | Age/Sex . | Therapy . | Rai Stage . | Lymphocyte Count (×109/L) . | Phenotype of B-CLL Analyzed* (T cell/NK cell/B cell, %) . |
|---|---|---|---|---|---|
| I-105 | 76/male | Pause | III | 89 | 0.6/0.6/95.3 |
| I-40 | 80/female | Adriamycin, low dose | III | 351 | 0.8/0.5/89.3 |
| I-90 | 68/male | Betapred | nd | 462 | 0.1/0.2/92.3 |
| I-276 | 72/female | Chlorambucil, cortisone, splenectomy | IV | nd | 0.9/0.9/93.8 |
| I-397 | 52/male | Cortisone, splenectomy | IV | 228 | 0.8/0.6/97.2 |
| I-424 | 77/male | Pause | III | 48 | 0.8/0.1/96.0 |
| RD-1 | 84/male | Leukeran | I | 199 | 0.2/0.1/96.7 |
| KAK-2 | 72/male | No therapy | IV | 233 | 0.6/2.1/77.7 |
| KK-32 | 74/male | No therapy | III | 103 | 2.0/0.5/96.6 |
| KF-65 | 82/male | No therapy | III | 40 | nd |
| LO-157 | 63/male | No therapy | I | 54 | 2.5/2.0/95.6 |
| KF-101 | 79/male | No therapy | II | 325 | 1.0/1.2/93.8 |
| LS-109 | 68/male | No therapy | IV | 223 | 0.02/0.1/95.9 |
| Patient Code . | Age/Sex . | Therapy . | Rai Stage . | Lymphocyte Count (×109/L) . | Phenotype of B-CLL Analyzed* (T cell/NK cell/B cell, %) . |
|---|---|---|---|---|---|
| I-105 | 76/male | Pause | III | 89 | 0.6/0.6/95.3 |
| I-40 | 80/female | Adriamycin, low dose | III | 351 | 0.8/0.5/89.3 |
| I-90 | 68/male | Betapred | nd | 462 | 0.1/0.2/92.3 |
| I-276 | 72/female | Chlorambucil, cortisone, splenectomy | IV | nd | 0.9/0.9/93.8 |
| I-397 | 52/male | Cortisone, splenectomy | IV | 228 | 0.8/0.6/97.2 |
| I-424 | 77/male | Pause | III | 48 | 0.8/0.1/96.0 |
| RD-1 | 84/male | Leukeran | I | 199 | 0.2/0.1/96.7 |
| KAK-2 | 72/male | No therapy | IV | 233 | 0.6/2.1/77.7 |
| KK-32 | 74/male | No therapy | III | 103 | 2.0/0.5/96.6 |
| KF-65 | 82/male | No therapy | III | 40 | nd |
| LO-157 | 63/male | No therapy | I | 54 | 2.5/2.0/95.6 |
| KF-101 | 79/male | No therapy | II | 325 | 1.0/1.2/93.8 |
| LS-109 | 68/male | No therapy | IV | 223 | 0.02/0.1/95.9 |
Cells, 25 000 in number, were analyzed by multicolor flow cytometry with the use of a Becton-Dickinson kit for leukocyte markers, according to manufacturer's recommendations. Gating was performed on CD45-positive cells. T-cell marker, CD3+; NK-cell markers, CD16+, CD56+, and CD3−; B-cell marker, CD19+.
nd = not determined. I-105 and I-424 were samples derived from the same donor, 1 year apart.